• BBES : Time to buy

  Report

  Reply
  Cancel Reply

• BBES : It means the price going to low. You can buy when it hit low price

  Report

  Reply
  Cancel Reply

• Trytosaveabit OP BBES : Means the company just got 3 million dollars and didn’t have to take a loan! Helps continue operations! Also right now there is almost no volume! I posted because it could be a good place to look to enter for a swing trade?? Someone paid 3 million and I’m sure it wasn’t without expecting a return on investment? NFA GL

  Report

  Reply
  Cancel Reply

• BBES Trytosaveabit OP : Just buy when it’s low.

  Report

  Reply
  Cancel Reply

• Trytosaveabit OP BBES : I will scale in! That way if it drops more? I can average down without spending more than what I was planning and still bring my average down if need be! Just like scaling out on the way up to protect profits and drop diluted cost allowing me to absorb bigger pullbacks while remaining in profit

  Report

  Reply
  Cancel Reply

• BBES : Hey time to buy now.

  Report

  Reply
  Cancel Reply

View more comments...

• Jaguar8 : No sell?

  Report

  Reply
  Cancel Reply

• Trytosaveabit OP Jaguar8 : It seems from all available data that I can find. All sell went straight to DP to probably be used for SS’s? JMO

  Report

  Reply
  Cancel Reply

• Jaguar8 Trytosaveabit OP : Grrr

  Report

  Reply
  Cancel Reply

• Trytosaveabit OP Jaguar8 : I know right! Like I said DP started as a well intentioned good thing! But it has turned into a place where corruption is made super easy and in the dark! And also now the norm! The way to hell is paved with good intentions! Hehehe

  Report

  Reply
  Cancel Reply

• Jaguar8 Trytosaveabit OP : How do they get into dark pool?

  Report

  Reply
  Cancel Reply

View more comments...

• Trytosaveabit OP : Following the sale of AxoBio, Carmell's financial position is expected to improve as follows:
  $4 million drop in annualized cash burn (net of revenue) based on AxoBio's actual January 2024 financials.
  $15.6 million reduction in debt: $7.6 million of AxoBio subsidiary level debt plus $8 million note payable related to the AxoBio acquisition.
  $7 million increase in tangible equity due to elimination of AxoBio's negative tangible equity.
  29% reduction in EPS dilution due to the return of 8.09 million CTCX common shares on a fully diluted basis. After closing, Carmell will have 19.25 million common shares outstanding.

  Report

  Reply
  Cancel Reply